Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.48 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.48 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26412229 | 0.87 | ALDH1A1 (0.51) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL15395718 | 0.83 | MEN1 (0.53) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL27822646 | 0.83 | TRPA1 (0.54) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL9681733 | 0.83 | MAPT (0.49) | CYP1A2CYP2C19ALDH1A1MAPTMEN1 | |
| SCHEMBL9681724 | 0.83 | MAPT (0.49) | CYP1A2CYP2C19ALDH1A1MAPTMEN1 | |
| SCHEMBL31118217 | 0.82 | MAPT (0.53) | CYP1A2CYP2C19ALDH1A1RAB9AMAPT | |
| SCHEMBL3377299 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3377294 | 0.81 | CYP1A2 (0.50) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL24611347 | 0.81 | LMNA (0.57) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL28330434 | 0.81 | LMNA (0.57) | CYP1A2CYP2C19ALDH1A1SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-7629372-B2 | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO., INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | MERCK & CO., INC. (US) | 2008-02-14 | — | — | US | disclosed |
| CN-101027056-A | Compounds for the treatment of dyslipidemia and other lipid disorders | MERCK & CO INC (US) | 2007-08-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039514-A1 | Compounds for the Treatment of Dyslipidemia and Other Lipid Disorders | LIPA, APOB, LCAT | CYP1A2 731/4885CYP2C19 976/4885ALDH1A1 660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.